Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP286169.RARUr8GSsu5RlRUqDV3uQe_-sRFbe2uEedGFvLc6n2E3A130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP286169.RARUr8GSsu5RlRUqDV3uQe_-sRFbe2uEedGFvLc6n2E3A130_assertion type Assertion NP286169.RARUr8GSsu5RlRUqDV3uQe_-sRFbe2uEedGFvLc6n2E3A130_head.
- NP286169.RARUr8GSsu5RlRUqDV3uQe_-sRFbe2uEedGFvLc6n2E3A130_assertion description "[In 56 specimens [CCH, n=1; MTC with CCH, n=26; MTC, n=20; lymph-node metastasis (LNM), n=9] from 46 patients [multiple endocrine neoplasia type 2a (MEN2a), n=24; MEN2b, n=2; familiar MTC (FMTC), n=4; sporadic MTC, n-16] and 3 cases of non-neoplastic CCH, proliferation activity (MIB1), the rate of apoptosis [dUTP nick end labelling (TUNEL)] and expression of p53, bcl-2, bcl-x and bax were investigated and compared with clinical data.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP286169.RARUr8GSsu5RlRUqDV3uQe_-sRFbe2uEedGFvLc6n2E3A130_provenance.
- NP286169.RARUr8GSsu5RlRUqDV3uQe_-sRFbe2uEedGFvLc6n2E3A130_assertion evidence source_evidence_literature NP286169.RARUr8GSsu5RlRUqDV3uQe_-sRFbe2uEedGFvLc6n2E3A130_provenance.
- NP286169.RARUr8GSsu5RlRUqDV3uQe_-sRFbe2uEedGFvLc6n2E3A130_assertion SIO_000772 11037345 NP286169.RARUr8GSsu5RlRUqDV3uQe_-sRFbe2uEedGFvLc6n2E3A130_provenance.
- NP286169.RARUr8GSsu5RlRUqDV3uQe_-sRFbe2uEedGFvLc6n2E3A130_assertion wasDerivedFrom befree-20140225 NP286169.RARUr8GSsu5RlRUqDV3uQe_-sRFbe2uEedGFvLc6n2E3A130_provenance.
- NP286169.RARUr8GSsu5RlRUqDV3uQe_-sRFbe2uEedGFvLc6n2E3A130_assertion wasGeneratedBy ECO_0000203 NP286169.RARUr8GSsu5RlRUqDV3uQe_-sRFbe2uEedGFvLc6n2E3A130_provenance.